Connecting Alzheimer’s Patients to Much-Needed Medical Research

CaringKind, New York City’s leading expert on Alzheimer’s and dementia caregiving for more than three decades, and Antidote Technologies, a digital health company that connects patients with clinical trials, today announced a partnership to address the ever-growing need for more and better Alzheimer’s research. Through this partnership, CaringKind now features Antidote Match, Antidote’s unique clinical trial matching tool, on its website.

Alzheimer’s affects approximately 5.4 million Americans and countless caregivers – and yet, it continues to be a disease that is not fully understood. There is no cure available and treatments are not always effective. But there’s good news: researchers across the country are focusing on this area more than ever. There are more than 160 open Alzheimer’s disease studies in the US. To be successful, however, these trials need more than 240,000 people to take part. And, with more trials planned, that number will only continue to grow.

CaringKind is an organization whose mission is to provide everyone affected by Alzheimer’s disease with the support they need, when they need it. For clinical trial matching, that support is Antidote Match, now available at http://www.caringkindnyc.org/clinicaltrials/. Match is a search technology that uses natural language processing and artificial intelligence to make it easier than ever for people to find their best clinical trial matches. Patients can be matched to trials just by answering a few questions. For patients, clinical trials often provide world-class care free-of-charge, and the knowledge that they are contributing to a future without Alzheimer’s disease.

Lou-Ellen Barkan, President and CEO of CaringKind, said, “In the absence of treatments or a cure for Alzheimer’s and dementia, the best medicine is good care. And while we at CaringKind are experts in helping caregivers provide the best possible care, Antidote is making clinical trials more accessible to everyone in the Alzheimer’s community. We are so proud to partner with Antidote and its revolutionary technology to help empower individuals who would like to do their part in furthering Alzheimer’s research.”

“We are facing a crisis in Alzheimer’s research,” said Pablo Graiver, Founder and CEO of Antidote. “Despite the fact that many new…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *